Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03386305
Other study ID # 5024
Secondary ID
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date December 13, 2017
Est. completion date December 31, 2021

Study information

Verified date January 2021
Source Albert Einstein Healthcare Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the medication adherence, clinical efficacy, and safety of EnvarsusXR in stable post liver transplant patient using a Phase III randomized controlled study. The primary outcome is change in medication adherence from baseline to the end of the study, assessed using a validated instrument (BAASIS- Basel Assessment of Adherence with Immunosuppressive medication Scales) and standard deviation of Tacrolimus levels.


Description:

The main aim of this study is to assess the immunosuppressant adherence, efficacy, and safety in post liver transplant patients converted from twice daily tacro to once daily EnvarsusXR. Tacrolimus trough level, clinical markers of liver disease, HbA1c , eGFR will be assessed at baseline, 1 week, 2 week, 4 week, 3 month and 6 months. Graft rejection will be assessed using routine standard guidelines to identify the cause. All patients post 1 year liver transplant, and within 5 years will be eligible to participate. The primary hypothesis is that once daily dosing will improve medication adherence in patients randomized to the test arm as compared to the control arm, over a period of 9 months. The clinical efficacy will be assessed by no difference in standard deviation of tacrolimus in the two groups. The secondary hypothesis is that improved medication adherence will lead to improved patient reported quality of life (as assessed by PROMIS-29), and better health outcomes (as assessed by HbA1c, eGFR).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 35
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patients who are 1 year post liver transplant, but within 5 years of transplant - Serum Creatinine<= 2.5 mg/dl; AST,ALT, AP and GGT<=2 times ULN - Patient must be on a stable tacrolimus dose, with tacrolimus trough levels between 5-12 ng/ml for 4 or more weeks before enrolment Exclusion Criteria: - Cognitive impairment which precludes participation - Projected survival, in the opinion of the provider, of less than three months - Any other solid organ transplant (kidney or pancreas) - Use of any drug which is known to interfere with tacrolimus metabolism

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EnvarsusXR
Patients randomized to study drug will be converted to EnvarsusXR once daily.
Tacrolimus
Patients continue to take Tacrolimus BID, as a part of routine care.

Locations

Country Name City State
United States Einstein Medical Center Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Albert Einstein Healthcare Network Veloxis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Medication Adherence Self reported using BAASIS instrument. BAASIS measures taking, skipping and dose reduction of drugs, with a recall period of 4 weeks. It consists of 4 questions with a 6 point response scale (ranging from never to every day). An additional overall adherence is ranked on a scale of 0 to 100 using a visual analog scale. From baseline to 6 months
Secondary Change in Quality of life Self reported, using PROMIS-29. PROMIS is a result of the NIH support to develop a "psychometrically validated, dynamic system to measure QOL and patient reported outcomes in study participants. PROMIS-29 comprises a set of 29 questions evaluating seven QOL domains: Physical function, anxiety, depression, fatigue, sleep disturbance, social function and pain. The scores are reported as a T score (mean 50, SD=10) centered on the sample representative of 2000 US general census considering demographic variables. From baseline to 6 months
See also
  Status Clinical Trial Phase
Completed NCT01687270 - Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant Phase 2
Active, not recruiting NCT05063071 - Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant Phase 4
Recruiting NCT06304467 - CM for Patients With ALD After Liver Transplant N/A